Rontalizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IFN-α |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
948570-30-7  |
| ChemSpider | none |
| UNII |
LDO2FIQ61I  |
| Chemical and physical data | |
| Formula | C6486H9990N1722O2026S44 |
| Molar mass | 145.9 kg/mol |
| (what is this?) (verify) | |
Rontalizumab is a humanized monoclonal antibody[1] being developed by Genentech.[2] As of November 2009, it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.[3]
References
- ↑ WHO Drug Information
- ↑ Genentech: Rontalizumab (rhuMAb IFN alpha)
- ↑ Clinical trial number NCT00962832 for "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)" at ClinicalTrials.gov
This article is issued from Wikipedia - version of the 11/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.